Article

Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer

2025-10-03

Abstract excerpt

Effective treatment for metastatic cancer has remained elusive due to the persistence of drug-resistant metastasis stem cells (MetSCs) that drive relapse. MetSCs are tumor cell subpopulations enriched for their ability to reinitiate and sustain metastatic growth, displaying phenotypic plasticity and resistance to chemotherapy. These cells express the L1 cell adhesion molecule (L1CAM), a transmembrane protein detec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 33f23da4-f6aa-5746-9ca5-30257e0a1a9a
DOI: 10.1101/2025.10.01.679843

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancerDOI 10.1101/2025.10.01.679843Read

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.Semantic proximity Read

Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous HistologySemantic proximity Read

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlSemantic proximity Read

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlSemantic proximity Read

Directed Evolution of PD-L1-Targeted Affibodies by mRNA DisplaySemantic proximity Read

Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.Semantic proximity Read

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaSemantic proximity Read

Welding PROxAb Shuttles: A modular approach for generating bispecific antibodies via site-specific protein-protein conjugationSemantic proximity Read

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.Semantic proximity Read

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read